PMC:3605436 / 9237-9898 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/3605436","sourcedb":"PMC","sourceid":"3605436","source_url":"http://www.ncbi.nlm.nih.gov/pmc/3605436","text":"Patient disposition and datasets analysed\nA total of 205 patients were screened and 10 patients were considered screening failures. All patients enrolled constituted the intention to treat population (ITT), (N = 195). A total of 31 withdrawals occurred over the trial, resulting in 164 patients completing the trial. The most common reasons were: adverse event, moved/long travel distance, informed consent withdrawn, antibodies against natalizumab and pregnancy/pregnancy wish (Fig. 1).\n10.1371/journal.pone.0058643.g001 Figure 1 Flow diagram of the TYNERGY trial.\nThe CONSORT flow diagram model showing enrolment, follow-up, and data analysis was applied.\n\nD","divisions":[{"label":"Title","span":{"begin":0,"end":41}},{"label":"Figure caption","span":{"begin":488,"end":660}},{"label":"Title","span":{"begin":532,"end":566}}],"tracks":[{"project":"NEUROSES","denotations":[{"id":"T203","span":{"begin":8,"end":19},"obj":"PATO_0001727"},{"id":"T204","span":{"begin":368,"end":372},"obj":"PATO_0000573"},{"id":"T205","span":{"begin":380,"end":388},"obj":"PATO_0000040"}],"attributes":[{"subj":"T203","pred":"source","obj":"NEUROSES"},{"subj":"T204","pred":"source","obj":"NEUROSES"},{"subj":"T205","pred":"source","obj":"NEUROSES"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"NEUROSES","color":"#93eccf","default":true}]}]}}